<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55466">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02086032</url>
  </required_header>
  <id_info>
    <org_study_id>OBG-2556-02070</org_study_id>
    <nct_id>NCT02086032</nct_id>
  </id_info>
  <brief_title>The Effect of Different Types of Progestin on Sleeping of Menopausal Women</brief_title>
  <official_title>The Effect of Different Types of Progestin on Sleeping of Menopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiang Mai University</source>
  <oversight_info>
    <authority>Thailand: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigators have found that sleeping disorder is an important problem in menopausal women.

      There have been papers reporting the effect of hormonal therapy on sleeping, but fews have
      reported the effect of different progestogens on sleeping quality. There is a need for more
      in-depth study and more conclusive evidence about the progestins which have the most
      beneficial effects on sleeping disorders in menopausal women.

      This study is going to collect the data from newly identified menopausal patients who are
      eligible for continuous estrogen-progestogen therapy for their climacteric treatment. The
      affects of the therapy will be monitored for 3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New patients who are eligible for hormonal therapy will be selected.

      They will be allocated randomly into 2 different groups, each group being prescribed 1 of 2
      regimens of hormonal therapy:

        -  17 beta estradiol 1mg/day plus oral micronized progesterone 100mg/day

        -  17 beta estradiol 1mg/day plus dydrogesterone 10mg/day Patients will have their
           sleeping quality accessed using the Pittsburgh sleep quality index(PSQI) at their 1st
           visit and once a month for 3 months. The first and third PSQI score will be analysed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improving of sleeping quality (assessed by the PSQI score)</measure>
    <time_frame>from March 2014 up to 15 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>The side effects comparing the 2 arms.</measure>
    <time_frame>from March 2014 up to 15 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Acne,melanoma, breast tenderness, abnormal vaginal bleeding, weight change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The climacteric symptoms comparing the 2 arms.</measure>
    <time_frame>from March 2014 up to 15 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>self reported of hot flash, fatigue and weakness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Menopausal and Postmenopausal Disorders</condition>
  <arm_group>
    <arm_group_label>micronized progesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 mg 17 beta-estradiol plus 100 mg micronized progesterone taken orally once a day for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dydrogesterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg 17 beta-estradiol plus 10 mg dydrogesterone taken orally once a day for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1mg 17 beta-estradiol</intervention_name>
    <description>Comparing sleeping quality between micronized progesterone and dydrogesterone users.</description>
    <arm_group_label>micronized progesterone</arm_group_label>
    <arm_group_label>dydrogesterone</arm_group_label>
    <other_name>Estrogen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone</intervention_name>
    <description>Comparing sleeping quality between micronised progesterone and dydrogesterone users.</description>
    <arm_group_label>dydrogesterone</arm_group_label>
    <other_name>Duphaston</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>micronized progesterone</intervention_name>
    <description>Comparing sleeping quality between micronised progesterone and dydrogesterone users</description>
    <arm_group_label>micronized progesterone</arm_group_label>
    <other_name>Utrogestan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  new menopausal patients at Maharaj Nakorn Chiang Mai Hospital

          -  suitable for estrogen plus progesterone treatment

        Exclusion Criteria:

          -  contraindication for hormone replacement therapy

          -  recently used sleep enhancing medicine

          -  recently used psychotic medicine
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tawiwan Pantasri, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, Chiang Mai University, Thailand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Obstetrics and Gynecology department, Faculty of Medicine, Chiang Mai University</name>
      <address>
        <city>Muang</city>
        <state>Chiang Mai</state>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tawiwan Pantasri, MD.</last_name>
      <phone>+66 53945552</phone>
      <email>tawiwan.p@cmu.ac.th</email>
    </contact>
    <investigator>
      <last_name>Ekachai Leeangkoonsathian, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 12, 2014</lastchanged_date>
  <firstreceived_date>March 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiang Mai University</investigator_affiliation>
    <investigator_full_name>Ekachai Leeangkoonsathian</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Sleeping quality</keyword>
  <keyword>menopause</keyword>
  <keyword>climacteric</keyword>
  <keyword>progestin</keyword>
  <keyword>dydrogesterone</keyword>
  <keyword>micronized progesterone</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dydrogesterone</mesh_term>
    <mesh_term>Progestins</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
